James Barsoum
Overview
Explore the profile of James Barsoum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woo C, Maier V, Davey R, Brennan J, Li G, Brothers 2nd J, et al.
Proc Natl Acad Sci U S A
. 2017 Feb;
114(8):E1509-E1518.
PMID: 28193854
Spinal muscular atrophy (SMA) is a neurodegenerative disease characterized by progressive motor neuron loss and caused by mutations in (). The disease severity inversely correlates with the copy number of...
2.
Foley K, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, et al.
J Pharmacol Exp Ther
. 2012 Jul;
343(2):529-38.
PMID: 22837008
Vascular disrupting agents (VDAs) are an emerging class of therapeutics targeting the existing vascular network of solid tumors. However, their clinical progression has been hampered because of limited single-agent efficacy,...
3.
Shimamura T, Perera S, Foley K, Sang J, Rodig S, Inoue T, et al.
Clin Cancer Res
. 2012 Jul;
18(18):4973-85.
PMID: 22806877
Purpose: We describe the anticancer activity of ganetespib, a novel non-geldanamycin heat shock protein 90 (HSP90) inhibitor, in non-small cell lung cancer (NSCLC) models. Experimental Design: The activity of ganetespib...
4.
Nagai M, Vo N, Ogawa L, Chimmanamada D, Inoue T, Chu J, et al.
Free Radic Biol Med
. 2012 May;
52(10):2142-50.
PMID: 22542443
Elesclomol is an investigational drug that exerts potent anticancer activity through the elevation of reactive oxygen species (ROS) levels and is currently under clinical evaluation as a novel anticancer therapeutic....
5.
Wada Y, Cardinale I, Khatcherian A, Chu J, Kantor A, Gottlieb A, et al.
PLoS One
. 2012 Apr;
7(4):e35069.
PMID: 22493730
Psoriasis is characterized by hyperplasia of the epidermis and infiltration of leukocytes into both the dermis and epidermis. IL-23, a key cytokine that induces T(H)17 cells, has been found to...
6.
Ying W, Du Z, Sun L, Foley K, Proia D, Blackman R, et al.
Mol Cancer Ther
. 2011 Dec;
11(2):475-84.
PMID: 22144665
Targeted inhibition of the molecular chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel...
7.
London C, Bear M, McCleese J, Foley K, Paalangara R, Inoue T, et al.
PLoS One
. 2011 Nov;
6(11):e27018.
PMID: 22073242
Background: The novel water soluble compound STA-1474 is metabolized to ganetespib (formerly STA-9090), a potent HSP90 inhibitor previously shown to kill canine tumor cell lines in vitro and inhibit tumor...
8.
Proia D, Foley K, Korbut T, Sang J, Smith D, Bates R, et al.
PLoS One
. 2011 May;
6(4):e18552.
PMID: 21533169
There is accumulating evidence that dysregulated JAK signaling occurs in a wide variety of cancer types. In particular, mutations in JAK2 can result in the constitutive activation of STAT transcription...
9.
Bansal H, Bansal S, Rao M, Foley K, Sang J, Proia D, et al.
Blood
. 2010 Jul;
116(22):4591-9.
PMID: 20651072
The aberrant overexpression of Wilms tumor 1 (WT1) in myeloid leukemia plays an important role in blast cell survival and resistance to chemotherapy. High expression of WT1 is also associated...
10.
Qu Y, Wang J, Sim M, Liu B, Giuliano A, Barsoum J, et al.
Breast Cancer Res Treat
. 2009 Jul;
121(2):311-21.
PMID: 19609669
Elesclomol is a small-molecule investigational agent that selectively induces apoptosis in cancer cells by increasing oxidative stress. Elesclomol plus paclitaxel was shown to prolong progression-free survival compared with paclitaxel alone...